DANIEL TINNEY: Open Payments
NPI 1780329110 · PARIS, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,968 in 110 payments from 22 companies in 2025. Trend: 2023 $822 · 2024 $1,412 · 2025 $1,968
Food & beverage: $1,960Education: $8
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $369 |
| Vanda Pharmaceuticals Inc. | 12 | $345 |
| Supernus Pharmaceuticals, Inc. | 19 | $177 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $174 |
| AstraZeneca Pharmaceuticals LP | 5 | $107 |
| Teva Pharmaceuticals USA, Inc. | 5 | $99 |
| Axsome Therapeutics, Inc. | 3 | $79 |
| GlaxoSmithKline, LLC. | 4 | $77 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $64 |
| Insulet Corporation | 3 | $63 |
Products named: VRAYLAR, HETLIOZ, CAPLYTA, Qelbree, FANAPT, FARXIGA, Auvelity, TRELEGY ELLIPTA.
Industry payments across KY — which companies pay providers there.
